MichelVelezMD

Oncology • Orlando, FL

Hematology/Oncology University of Miami

Join to view full profile

Dr. Velez is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Velez's full profile

Already have an account?

Office
6400 Sanger Rd
Ste A-2400
Orlando, FL 32827
Phone+1 407-735-5695

Fax+1 407-851-4630

Education & Training

University of Miami/Jackson Health SystemFellowship, Hematology and Medical Oncology, 2011 - 2014
University of Miami Hospital and Clinics/Holy Cross HospitalResidency, Internal Medicine, 2008 - 2011
Universidad del Norte Faculty of MedicineClass of 2000

Certifications & Licensure

FL State Medical License 2014 - 2026

Publications & Presentations

PubMed

2 citations
EGFR L718V (+)/T790M (-) as a Mechanism of Resistance in Patients with Metastatic Non-small-cell Lung Cancer with EGFR L858R Mutations.
Luis E. Raez, Carlos Carracedo, Leylah M. Drusbosky, Michel Velez, Jennifer W Carlisle
Clinical Lung Cancer. 2021-04-09
1 citations
Evaluation of weekly paclitaxel plus carboplatin followed by anthracycline chemotherapy on the neoadjuvant treatment of patients with triple-negative breast cancer.
Aurelio Castrellon, Michel Velez, Steven M. Nguyen, Marcelo Blaya, Sandra Barnick
Hematology/oncology and Stem Cell Therapy. 2017-10-01
61 citations
Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma
Moh’d Khushman, Naomi Dempsey, Jennifer Cudris Maldonado, Arturo Loaiza-Bonilla, Michel Velez
Pancreatology. 2015-11-01

Press Mentions

UCF’s Cancer Center in Lake Nona Begins Taking Shape as Florida Cancer Specialists Finds New HomeFebruary 24th, 2021
Florida Cancer Specialists & Research Institute Welcomes Dr. Michel VelezDecember 28th, 2020
Key Trials Showcase the Utility of Neratinib in HER2+ Breast CancerAugust 9th, 2019